“Glucagon-like Peptide-1 Receptor Agonist Treatment in Type 1 Diabetes: A Review of Current Evidence and Rationale for Use”, Can Diabetes Endocrinol Today, vol. 1, no. 3, pp. 21–26, Oct. 2023, doi: 10.58931/cdet.2023.1318.